Everything you ever wanted to know about diet drugs -- but were afraid to ask!

OMR 2000 publishes its annual edition of the treatments. October 10, 2000. OBESITY MEDS and Research News (OMR) has published its annual report problem current drug development. This annual edition presents an overview of: - all known obesity gene discovered in the last year. - Drugs currently used are now studying for obesity. - The anti-obesity drugs in clinical trials. - The genes and molecules in preclinical development. - News from different drug development. - A list of resources for drug development. some subscribers have referred to this issue, as OMR's Sports Illustrated Swimsuit Edition. We will not have any pictures of women in bikinis in this month (maybe two nude mice), but you will get valuable information about drugs in the coming years, you or your patients on the road to a healthier life - perhaps even in that bathing suit! All elements of this month's issue concerns the development of new drugs against obesity and news on existing medicines. If you want to know when the next generation of drugs will be available for this issue is a must! The main feature of this edition, each year is our drug development calendar gives readers an overview of all prescription anorectics also be created, information on pharmaceutical companies developing drugs, the development process, how works and more. Here is an example of a problem this year: Botanical Drug: CP-644, 694 (P57) stages: a phase II Developer: Phytopharm Pfizer and what it does. Suppresses appetite. MORE INFORMATION. P57 is extracted from a cactus in South Africa. Phytopharm has six patents pending in the use of the plant, its active molecules, derivatives and mode of action. Once your patent is published enterprises provide the mode of action. Dr. Richard Dixey, Phytopharm's CEO, the Wall Street Journal (WSJ), "We do not disclose the mode of action at this time, because P57 is the subject of very active patienting. There is no common point in the phase that initial information until the patent is finally published and publicly available information. All I could do was give the information of potential competitors. In 1997, Phytopharm licensed the rights to P57 by the Council for Scientific and Industrial Research of South Africa. Only about 5 percent of the 250,000 species of plants were tested for medicinal purposes. 2000 update. June 12, 2000 According to the WSJ article, four Phase I studies completed in April 2000, but no data has been released. In August 2000, the company announced that its collaboration with Pfizer in P57 would be extended. Phase II is scheduled for early autumn. If you are interested in new drugs, weight loss, this problem is in a single purchase, you must read! Only OBESITY MEDS and research NEWS. OBESITY MEDS and research press is a simple monthly newsletter covers the language of the latest research on obesity and weight loss. The newsletter is available online with a password, or in paper form by priority mail. Selected articles from the full text editing are available for non-subscribers. To view the stories accessible to the public, go to the archives of OMR. Contact: Barbara Hirsch, Publisher, medicines and NEW "search, PO Box 19316th, Alexandria, VA 22320-0316, telephone: 703/960-3649, fax 703 / 960-7462, e-mail: subscriptions @ press obesity. com.